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Increased KGF Expression Promotes Fibroblast
Activation in a Double Paracrine Manner Resulting in
Cutaneous Fibrosis
Johanna Canady1, Stephanie Arndt1, Sigrid Karrer2 and Anja K. Bosserhoff1
Fibrotic disorders of the skin share the characteristic features of increased production and deposition of
extracellular matrix components by activated fibroblasts. Their clinical course ranges from benign with localized
cutaneous involvement to a systemic, life-threatening disease. The molecular cause for fibroblast activation
remains unknown, yet epithelial–mesenchymal interactions draw mounting attention in the research field of
fibrogenesis. We examined keratinocyte growth factor (KGF), a crucial molecule in fibroblast–keratinocyte cross
talk, exemplarily in keloid and scleroderma, and found its expression to be increased in disease-derived
fibroblasts and tissues compared with healthy controls. This overexpression induces fibroblast activation through
a double paracrine mode of action. Upon KGF stimulation, the keratinocytes produced and secreted OSM
(oncostatin M). Fibroblasts were in turn activated by OSM reacting with the increased expression of collagen type
I-a1, fibroblast activation protein, and enhanced migration. The observed increase in collagen expression and
fibroblast migration can be traced back to OSM-regulated STAT3 phosphorylation, leading to enhanced
urokinase plasminogen activator expression. Hence, we propose a causative loop in the pathogenesis of
fibrosing disorders of the skin mediated by the overexpression of KGF in mesenchymal cells.
Journal of Investigative Dermatology (2013) 133, 647–657; doi:10.1038/jid.2012.389; published online 25 October 2012
INTRODUCTION
Cutaneous fibrosis is the result of excessive ECM (extracellular
matrix) synthesis and deposition and a characteristic feature
of fibrosing connective tissue disorders, such as keloid and
scleroderma (Werner and Grose, 2003; Denton et al., 2006).
Keloids occur as an impaired wound healing response to
cutaneous injury and are defined as scars growing beyond the
original wound boundaries (Syed et al., 2011). Scleroderma,
on the other hand, designates a variety of autoimmune
disorders differing in severity and the organs affected
(Romano et al., 2011). However, all of these conditions
share a common feature: an overexuberant deposition of
collagen and other ECM components because of an
activation of dermal fibroblasts. A genetic cause can be
presumed as several predispositions could be observed:
keloid prevalence is much higher in dark pigmented
populations (Bran et al., 2009), whereas scleroderma
predominantly affects women, and additionally, familial
clustering has been reported (Vilela et al., 2010; Romano
et al., 2011). So far, the molecular trigger for the enhanced
collagen production and deposition remains unknown.
Currently, approved treatments that directly target the
mechanisms of fibrosis are still an unmet clinical need.
Fibroblasts are considered the culprit cell type in fibrosing
connective tissue disorders, as their activation leads to the
overproduction of ECM components (Wynn, 2007; Huang and
Ogawa, 2012). The exact accomplishment of this activation is
still not clear, but recent evidence indicates that epithelial–
mesenchymal cross talk has a critical role in fibrosing
connective tissue disorders (Krieg et al., 2007). Epithelial
cells were reported to activate the underlying fibroblasts and
thereby contributing to fibrosis, for instance, in idiopathic lung
fibrosis (Selman and Pardo, 2002) and in systemic sclerosis
(Aden et al., 2010). In addition, keloid fibroblasts were shown
to produce strongly enhanced levels of collagen in coculture
compared with monoculture (Phan et al., 2002). The studies
underlining the impact of epidermal–dermal interactions are
numerous.
One of the crucial molecules for epithelial–mesenchymal
cross talk and cutaneous wound healing is keratinocyte
growth factor (KGF) , a member of the fibroblast growth factor
family (FGF7). The peculiarity of KGF is based on its paracrine
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mode of action: in the skin, where KGF is mainly expressed
and released by dermal fibroblasts but acts exclusively on
epidermal keratinocytes, which express the KGF receptor
(KGFR), the splice variant IIIb of the fibroblast growth factor
receptor 2 (FGFR2IIIb). After wounding, the expression of KGF
is highly increased through fibroblast–keratinocyte interactions
and subsequently increases dermal keratinocyte proliferation
and migration enhancing reepithelialization (Beer et al., 2000;
Werner et al., 2007). Moreover, Staiano-Coico et al. (1993)
and Jimenez and Rampy (1999) revealed that exogenously
applied KGF on granulation tissue leads to increased collagen
deposition.
For these reasons, we analyzed the KGF expression status in
the context of keloid and scleroderma. As we found KGF to be
upregulated in disease-derived fibroblasts, we speculated
whether KGF could indirectly lead to fibroblast activation by
stimulating keratinocytes to release profibrotic factors.
RESULTS
KGF is upregulated in keloid and scleroderma
Activation of fibroblasts and consequent increased production
and deposition of ECM components are characteristic for
fibrosing connective tissue disorders of the skin, such as keloid
and scleroderma. As mentioned above, Collagen type I-a1
(ColIa1) is highly expressed in keloid and scleroderma tissue.
Similarly, the expression of fibroblast activation protein-a
(FAP-a) is known to be restricted to activated fibroblasts
(Dienus et al., 2010). Therefore, both molecules represent
suitable fibroblast activation markers, as we could substantiate
isolating RNAs from healthy and disease-derived tissue
(Figure 1a and b). The exact cause of fibroblast activation
remains unknown but it is speculated to be a result of altered
fibroblast–keratinocyte interactions (Krieg et al., 2007). As
KGF is a very important molecule in epithelial–mesenchymal
cross talk, we decided to analyze its role in fibrosing disorders
of the skin. Notably, we found its expression to be constitu-
tively increased in keloid (KF)- and scleroderma (SF)-derived
fibroblasts, respectively, compared with normal fibroblasts
(NFs), as well as on messenger RNA (mRNA; Figure 1c) and
on protein levels (Figure 1d). Interestingly, this upregulation
was persistent in cell culture even in later passages, indicating
that a genetic alteration rather than an external trigger leads to
the increased KGF secretion. KGF protein levels were also
significantly enhanced in the sera of keloid and scleroderma
patients compared with the sera of healthy individuals
(Figure 1e), which is striking, as commonly only fractional
parts of the skin are affected. Examining the tissue of keloid
and scleroderma patients, KGF expression was equally
increased in disease-derived tissue compared with normal
skin as well as on mRNA (Figure 1f) and on protein levels
detected by immunohistochemistry (Figure 1g, Supplementary
Figure S1 online).
Enhanced KGF levels induce fibroblast activation in a double
paracrine manner
We hypothesized that the enhanced KGF levels found in
keloid and scleroderma may contribute to fibroblast activation
in a double paracrine manner (Figure 2a). Therefore, normal
human epidermal keratinocytes (NKs) were cultured with the
conditioned media (CM) of normal (nFCM) and disease-
derived fibroblasts (kFCM and sFCM), respectively. After
24 hours, the respective CM were transferred from the NKs
onto normal human dermal fibroblasts (NFs) and hitherto
effects on fibroblast activation were examined (Figure 2a).
Fibroblast activation was determined analyzing the expression
levels of ColIa1 and FAP, and by examination of fibroblast
proliferation and migration. The expression of both activation
markers was significantly increased when NFs were treated
with the supernatants of NKs previously incubated with the
CM of KFs and SFs (KCM (keratinocyte-conditioned med-
ium):kFCM and KCM:sFCM), respectively, compared with the
CM of keratinocytes incubated with NF supernatants
(KCM:nFCM) (Figure 2b and c). In addition, although fibro-
blast proliferation was unaltered, fibroblast migration in
scratch wound healing assays was also increased when NFs
were incubated with KCM:kFCM and KCM:sFCM, respec-
tively, compared with KCM:nFCM (Figure 2d).
To control that keratinocytes are indeed necessary to exert
the fibroblast activating effects, we applied the FCM directly
on NFs. Neither of the FCM was able to induce fibroblast
activation directly (Supplementary Figure S2 online).
We could corroborate our hypothesis of KGF having a
crucial role in fibroblast activation, as the observed activation
could also be induced by KGF alone: NFs incubated with the
CM of NKs directly treated with recombinant KGF (KCMþ
rKGF), or incubated with CM of NFs transfected with a KGF-
expression plasmid (KCM:nFCM:KGF) showed enhanced
induction of ColIa1 and FAP expression compared with the
CM of untreated NKs (KCM), or NKs incubated with the
supernatants of mock-transfected NFs (KCM:nFCM:mock)
(Figure 2e and f). Although proliferation was again not
influenced, the migration of fibroblasts was significantly
enhanced in scratch wound-healing assays in the same KGF-
dependent manner (Figure 2g).
We could substantiate that fibroblast activation occurred
depending on KGF, as decrease of KGF resulted in lower
activation. The expression of both activation markers and
fibroblast migration were reduced when the fibroblasts were
incubated with supernatants of keratinocytes, which were
pretreated with CM from KFs or SFs transfected with KGF
small interfering RNA (siRNA; KCM:kFCM:siKGF,
KCM:sFCM:siKGF) compared with control transfected ones
(KCM:kFCM:siCTRL, KCM:sFCM:siCTRL) (Figure 2h, i, and j).
KGF induces keratinocytes to release OSM leading to fibroblast
activation
The observed fibroblast activation correlating with enhanced
KGF levels must be because of a double paracrine fibroblast–
keratinocyte interaction, as fibroblasts do not express the
KGFR (Miki et al., 1992) and, therefore, an autocrine mode
of action can be excluded (see Supplementary Figure S3
online). To identify which cytokines are secreted by keratino-
cytes upon KGF stimulation, possibly inducing the enhanced
fibroblast activation, a RayBio Human Cytokine Antibody
Array was performed with CM of keratinocytes treated with
20 ng recombinant KGF per microliter for 24 hours compared
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with untreated ones. Oncostatin M (OSM) was the only
cytokine whose expression was altered donor independently
upon KGF treatment. The secretion levels of all other secreted
cytokines were unaltered upon KGF stimulation. The results of
the cytokine array were confirmed on mRNA level using
reverse transcriptase–PCR (RT-PCR; Supplementary Table S1
online).
As anticipated, OSM mRNA expression of keratinocytes was
increased when the cells were cultured with the CM of KFs
(kFCM) and SFs (sFCM), respectively, compared with the CM
of NFs (nFCM) (Figure 3a). Performing an OSM ELISA, we
further measured highly increased OSM protein levels in the
CM of the NKs incubated with recombinant KGF and keloid
and scleroderma fibroblast CM (þ kFCM and þ sFCM),
respectively, whereas OSM protein levels were barely detect-
able in the supernatants of untreated NKs or NKs incubated
with nFCM (Figure 3b). Most notably, the effect observed after
the incubation with KCMþ rKGF, KCM:kFCM or KCM:sFCM,
obviously containing OSM, on the expression of FAP
(Figure 3c) and ColIa1 (Figure 3d) could also be induced by
directly treating the NFs, KFs, or SFs with recombinant OSM
(10 ng ml 1). Fibroblast migration was also inducible by
recombinant OSM treatment alone (Figure 3e). More impor-
tantly, we were able to confirm that the OSM secretion is
clearly because of KGF stimulation, as NKs transfected with
siRNA against KGFR (siKGFR) failed to express the increased
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Figure 1. Increased keratinocyte growth factor (KGF) expression in keloid and scleroderma. (a) Collagen type I-a1 (ColIa1) and (b) fibroblast activation
protein (FAP) messenger RNA (mRNA) expression in keloid tissue (n¼ 4) and scleroderma tissue (n¼ 4) x-fold compared with normal skin (n¼5) were analyzed by
reverse transcriptase–PCR (RT-PCR). (c) KGF mRNA levels of keloid fibroblasts (KFs; n¼ 4) and scleroderma fibroblasts (SFs; n¼ 5) compared with normal
fibroblasts (NFs; n¼ 5) analyzed by RT-PCR. The graphs represent mean values of four independent experiments, and error bars represent the mean±SD of these
experiments analyzed with analysis of variance (ANOVA)þKruskal–Wallis test. (d, e) The KGF protein levels in the conditioned media (d) and in the sera of keloid
(n¼ 30) and scleroderma patients (n¼ 20) compared with healthy individuals (n¼15) (e) were measured by ELISA and analyzed with ANOVAþTukey test.
(f) KGF mRNA expression in keloid tissue (n¼ 7) and scleroderma tissue (n¼ 7) x-fold compared with normal skin (n¼ 6) analyzed by means of RT-PCR and
ANOVAþ Tukey test. (g) Immunohistochemistry with anti-KGF antibody. KGF-positive fibroblasts in diseased dermis are stained brownish compared with
unstained fibroblasts in normal dermis. Representative samples are depicted.
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OSM levels after KGF stimulation in contrast to the control-
transfected NKs (siCTRL) (Figure 3f). In addition, KGF-induced
OSM expression was reduced when KGF was inhibited using
KGF-neutralizing antibodies in the CM of disease-derived
fibroblasts (Supplementary Figure S4 online).
Interestingly, examining the OSM expression in tissue
samples, we found it to be significantly overexpressed in
keloid and scleroderma tissue compared with normal skin
(Figure 3g).
KGF overexpression induces STAT3-signaling via OSM
So far, we could demonstrate that the enhanced KGF expres-
sion by keloid and scleroderma fibroblasts induces NKs to
secrete OSM, which in turn induces fibroblast activation.
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Figure 2. Keratinocyte growth factor (KGF) enhances fibroblast migration in a double paracrine manner. (a) Experimental setup. (b) Collagen type I-a1 (ColIa1)
and (c) fibroblast activation protein (FAP) messenger RNA (mRNA) expression and (d) migratory behavior in normal fibroblasts (NFs) treated with the conditioned
media of keratinocytes (KCM) preincubated with conditioned media of KFs (kFCM) and SFs (sFCM), respectively, compared with NFs treated with KCM of
keratinocytes precultured with the conditioned media of normal fibroblasts (nFCM). (e) The ColIa1 and (f) FAP mRNA expression in NFs upon incubation with
KCM of keratinocytes (NKs) directly treated with recombinant KGF (KCMþKGF) or KGF-transfected keratinocytes (KCM:KGF) compared with untreated (KCM)
and mock-transfected keratinocytes (KCM:mock), respectively. (g) Migration of NFs after 24 hours incubation with KCMþKGF or KCM:KGF compared with KCM
alone KCM:mock, respectively, as well as upon incubation with KCM of keratinocytes preincubated with nFCM of KGF-transfected NFs (KCM:nFCM:KGF)
compared with mock-transfected NFs (KCM:nFCM:mock). (h) The ColIa1, (i) FAP mRNA expression, and (j) fibroblast migration after treatment with KCM of
keratinocytes preincubated with FCM of KGF small interfering RNA (siRNA)–transfected KFs and SFs (KCM:kFCM:siKGF and KCM:sFCM:siKGF), respectively,
compared with control siRNA–transfected KFs and SFs (KCM:kFCM:siCTRL and KCM:sFCM:siCTRL). The graphs represent mean values of three independent
experiments, and error bars represent the mean±SD of these experiments analyzed with (b–d) analysis of varianceþKruskal–Wallis test and (e–j) Mann–Whitney
test, respectively.
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OSM is known to interact with type I and type II OSM
receptor. The signal transduction pathway involves activation
of the signal transducer and activator of transcription (STAT)
family (Dreuw et al., 2005).
We found OSM to strongly induce STAT3 phosphoryla-
tion in fibroblasts when the cells were directly treated with
recombinant OSM. Incubation of NFs with CM from
keratinocytes, which were cultured with supernatants from
keloid- or scleroderma-derived fibroblasts (KCM:kFCM and
KCM:sFCM, respectively) or treated with recombinant KGF
(KCMþ rKGF), also lead to strong STAT3 phosphorylation.
No phosphorylation was detectable when the fibroblasts
were incubated with supernatants from untreated keratino-
cytes or from keratinocytes cultured with the CM of NFs
(KCM:nFCM) (Figure 4a). These results are in agreement
with the high OSM levels measured in KCM:kFCM,
KCM:sFCM, and KCMþ rKGF, in contrast to KCM:nFCM
or KCM alone. We also treated the fibroblasts directly with
recombinant KGF (þ rKGF) to exclude any sort of unspecific
activating effects (Figure 4b). What is more, the activation
was decreased when the fibroblasts were treated with
supernatants from keratinocytes incubated with CM from
KGF siRNA-treated KFs (KCM:kFCM:siKGF) compared with
KCM:kFCM:siCTRL. Moreover, phosphorylation of STAT3
*
**
***
***
***
*
3.0
3.5 800
700
600
500
400
10
5
0
O
SM
 p
ro
te
in
(pg
 m
l–1
)
2.0 **
1.5
1.0
0.5
0.0
2.0
1.5
1.0
0.5
0.0
NF
NF
 + 
OS
M
600 Untreated
+KGF
2.0 45.0
37.5
30.0
22.5
15.0
7.5
0.0
Sk
in
Ke
loid
Sc
ler
od
erm
a
NS
1.5
1.0
0.5
0.0
siCTRL siKGFR
***
*
**
**
*
*
*500
400
300
200
100
0
Fi
br
ob
la
st
 m
ig
ra
tio
n
(μm
)
O
SM
 m
RN
A
(x-
fol
d t
o u
ntr
ea
ted
) 
O
SM
 m
RN
A
(x-
fol
d t
o n
orm
al 
sk
in)
Untreated +OSM
Un
tre
ate
d
+O
SM KF
KF
 + 
OS
M SF
SF
 + 
OS
M KF
KF
 + 
OS
M SF
SF
 + 
OS
M
FA
P 
m
R
N
A
(x-
fol
d t
o u
ntr
ea
ted
)
Co
llα
1 
m
R
N
A
(x-
fol
d t
o u
ntr
ea
ted
)
2.5
2.0
1.5
1.0
0.5
0.0
Un
tre
ate
d
+K
GF
nF
CM
kF
CM
sF
CM
O
SM
 m
RN
A
(x-
fol
d t
o r
es
pe
cti
ve
 co
ntr
ol)
Un
tre
ate
d
+r
KG
F
+n
FC
M
+k
FC
M
+z
FC
M
Figure 3. Normal human epidermal keratinocytes (NKs) secrete oncostatin M (OSM) upon keratinocyte growth factor (KGF) stimulation inducing fibroblast
activation. (a) The OSM messenger RNA (mRNA) expression analyzed in NKs after 24 hours treatment with recombinant KGF compared with untreated NKs and
kFCM and sFCM treatment compared with incubation with nFCM. The graph represents mean values of three independent experiments, and error bars represent
the mean±SD of these experiments with n¼ 3 for each sample analyzed with analysis of variance (ANOVA)þKruskal–Wallis test. (b) OSM protein measured by
ELISA secreted by NKs upon direct treatment with recombinant KGF (n¼ 6) compared with untreated NKs (n¼ 7) and upon incubation with kFCM and sFCM
compared with nFCM (each n¼5). The graph represents mean values of two independent experiments analyzed with ANOVAþ Tukey test. (c) Collagen type I-a1
(ColIa1) and (d) fibroblast activation protein (FAP) mRNA expression in normal fibroblasts (NFs), KFs, and scleroderma fibroblasts (SFs) with and without OSM
treatment. (e) Fibroblast migration after treatment with recombinant OSM (10 ng ml 1). (f) OSM mRNA expression upon KGF-treatment in NKs transfected with
control small interfering RNA (CTRL siRNA) and siRNA against KGFR (each n¼ 3). The graphs represent mean values of three independent experiments, and error
bars represent the mean±SD of these experiments analyzed with Mann–Whitney test. (g) The OSM mRNA expression in keloid tissue (n¼ 4) and scleroderma
tissue (n¼ 4) compared with normal skin (n¼ 5). The graphs represent mean values of three independent experiments, and error bars represent the mean±SD of
these experiments analyzed with ANOVAþKruskal–Wallis test.
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was induced after incubation with nFCM from NFs trans-
fected with a KGF-overexpression vector (KCM:nFCM:KGF),
whereas incubation with KCM:nFCM:mock did not
result in STAT3 activation (Figure 4b). To demonstrate that
OSM in fact induces STAT3 activation in healthy and
disease-derived fibroblasts, we treated NFs, KFs, and SFs
with recombinant OSM for 15 minutes and determined the
STAT3 phosphorylation status. Our results illustrate that the
STAT3 signaling is activated upon OSM treatment in normal
and disease-derived fibroblasts alike (Figure 4c). Further-
more, we could demonstrate that the STAT3 activation
occurs only in dependence of OSM. STAT3 phosphorylation
following incubation with rOSM, KCM:kFCM, and
KCM:sFCM was completely abolished when neutralizing
antibodies against OSM (antiOSM; R&D Systems MAB295)
were added to the KCM (1 mg ml 1) before transferring them
onto the NFs (Figure 4d).
STAT3 phosphorylation is responsible for fibroblast activation
Investigating the impact of STAT3 signaling on fibroblast
activation, we cultured NFs with STAT3 inhibitor S3I-201
during OSM treatment. Strikingly, we could indeed
abolish the activating effect of OSM on ColIa1 expression
(Figure 5a). Furthermore, OSM-induced fibroblast migration
could also be suppressed by means of pretreatment with S3I-
201 (Figure 5b).
More than that, we found the urokinase-type plasminogen
activator (uPA), a described migration-associated STAT3 target
gene (Dauer et al., 2005) responsible for increased fibroblast
migration. uPA is a serine protease crucial for a variety of
cellular processes, including tissue remodeling, cell migration,
and angiogenesis (Postiglione et al., 2010). We examined the
uPA expression and found it to be increasingly expressed in
NFs, following direct treatment with recombinant OSM as
well as after incubation with KCM:kFCM, KCM:sFCM, and
KCMþKGF. The uPA expression was unaltered after
incubation with KCM:nFCM (Figure 5c). Consistently, the
uPA expression was also increased in disease-derived fibro-
blasts upon OSM treatment (Figure 5d).
Enhanced NF migration upon incubation with recombinant
OSM and OSM containing media (KCM:kFCM and
KCM:sFCM), respectively, could be completely suppressed
when the NFs were simultaneously transfected with uPA
siRNA (Figure 5e).
In addition, we found uPA to be strongly expressed in keloid
and scleroderma tissue compared with normal skin (Figure 5f).
Being a STAT3 target gene, OSM-induced uPA overexpres-
sion could also be prevented utilizing S3I-201 (Figure 5g),
which offers a further possibility to interfere with fibroblast
activation.
Treatment of human skin with recombinant KGF leads to the
expression of fibrotic markers
To substantiate the in vivo relevance of our findings, we used
pieces of human skin and cultivated them in the presence
or absence of recombinant KGF. After 24 and 48 hours,
Un
tre
at
ed
NF NF
 +
 O
SM
NF
 +
OS
M
NF
 +
OS
M
+a
nt
iO
SM
NF
:K
CM
:n
FC
M
NF
:K
CM
:n
FC
M
+a
nt
iO
SM
NF
:K
CM
:kF
CM
NF
:K
CM
:kF
CM
+a
nt
iO
SM
NF
:K
CM
:sF
CM
NF
:K
CM
:sF
CM
+a
nt
iO
SM
KF KF
 +
 O
SM
SF SF
 +
 O
SM
+
 O
SM
KC
M:
nF
CM
KC
M:
kF
CM
KC
M:
sF
CM
KC
M
KC
M+
rK
GF
Un
tre
at
ed
+
 O
SM
+
rK
GF
KC
M:
kF
CM
:si
CT
RL
KC
M:
kF
CM
:si
KG
F
KC
M:
nF
CM
:m
oc
k
KC
M:
nF
CM
:K
GF
pSTAT3
pSTAT3
STAT3
pSTAT3
STAT3
β-Actin
β-Actin
STAT3
pSTAT3
STAT3
β-Actin
β-Actin
Figure 4. STAT3 is activated in fibroblasts upon keratinocyte growth factor (KGF)–induced oncostatin M (OSM) secretion. Western blot analyis was performed
for STAT3 and phosphorylated STAT3 (pSTAT3) using b-actin as a loading control. (a) STAT3 is constitutively expressed in normal fibroblasts (NFs) but
phosphorylation only occurs upon direct OSM treatment or treatment with OSM-containing keratinocyte-conditioned media (KCMs) as confirmed by the OSM
ELISA in Figure 3c. (b) Direct KGF treatment had no unspecific effect on STAT3 phosphorylation. NFs showed decreased STAT3 phosphorylation when treated
with KCM:kFCM:siKGF compared with KCM:kFCM:siCTRL, but increased phosphorylation after treatment KCM:nFCM:KGF compared with KCM:nFCM:mock.
(c) pSTAT3 and STAT3 expression status in NFs, keloid fibroblasts (KFs), and scleroderma fibroblasts (SFs) upon treatment with recombinant OSM. (d) pSTAT3
and STAT3 expression in NFs treated with rOSM and KCM in the presence or absence of OSM-neutralizing antibodies (þ antiOSM).
J Canady et al.
KGF Promotes Cutaneous Fibrosis in a Double Paracrine Manner
652 Journal of Investigative Dermatology (2013), Volume 133
respectively, we isolated RNA from the tissue samples and
analyzed the expression status of the factors involved in our
predicted double paracrine feedback loop. Most strikingly, we
found that the expression levels of OSM, FAP, ColIa1, and
uPA significantly increased upon KGF treatment in a time-
dependent manner (Figure 6a–d).
Taken together with this work, we present a mechanism of
fibroblast activation in skin fibrosis because of an increased
KGF expression schematically depicted in Figure 6e. We
could show that keratinocytes secrete high levels of OSM
upon KGF stimulation. The OSM containing keratinocyte-CM
exert profibrotic effects on fibroblasts by enhancing ColIa1
and FAP expression, as well as fibroblast migration. The
strengthened migratory activity could be traced back
to STAT3 phosphorylation resulting in increased expression
of uPA.
DISCUSSION
Epithelial–mesenchymal cross talk has a very important role in
skin homeostasis. Therefore, we investigated the expression of
KGF, a crucial molecule for fibroblast–keratinocyte interac-
tions in fibrosing cutaneous disorders, namely keloid and
scleroderma. We revealed a complex interplay of cytokines
between disease-derived fibroblasts and normal keratinocytes
resulting in fibroblast activation. Interestingly, we were able to
show KGF to be constitutively overexpressed by disease-derived
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fibroblasts andin patient skin samples. As KGF enhances
keratinocyte proliferation, this finding might explain why
keloids were repeatedly reported to have thickened epidermis
compared with normal skin/scars (Kischer et al., 1982; Ong
et al., 2010), and why NKs formed thicker epidermis when
cocultured with KFs in an organotypic culture (Butler et al.,
2008). Transgenic mice, overexpressing KGF in all their
epithelial cells under the control of the keratin-14 promoter,
show a great increase in epidermal thickness accompanied by
alterations in epidermal growth and differentiation (Guo et al.,
1993). On the other hand, in scarless repair, FGFs were shown
to be downregulated (Dang et al., 2003), which would also
support our data.
The persistence of the increased KGF expression in vitro
could be indicative for a genetic cause. We hypothesize that
affected individuals show KGF upregulation in all of their
mesenchymal cells that remains without consequence until
another secondary stimulus occurs. The elevated levels of KGF
protein in the sera of keloid and scleroderma patients are
another hint suggesting that also fibroblasts outside the
affected areas are overexpressing KGF.
Knowing that KGF cannot mediate direct effects on fibro-
blasts as they lack the KGFR, we were thrilled to discover a
double paracrine mode of fibroblast activation after incubating
normal keratinocytes with the respective CM before putting it
again on NFs. Performing a cytokine array to detect the factors
secreted by keratinocytes upon KGF stimulation, we found
only one cytokine whose expression was upregulated in a
donor-independent manner: OSM, a pleiotropic cytokine of
the IL-6 family, whose members are involved in numerous
cellular processes, such as inflammation, autoimmunity, and
cancer (Silver and Hunter, 2010). All these cytokines bind
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receptor complexes, which include the gp130 signaling
subunit as well as receptor-specific chains. OSM is a 28-
kDa glycoprotein originally described to inhibit tumor cell
growth. Further, it is known to have multiple biological
activities such as modulation of proliferation, embryonic
development, differentiation, inflammation, and regeneration
of various tissues. Moreover, in numerous studies, OSM has
been shown to have profibrotic properties in various tissues: it
potently stimulates fibroblasts to synthesize procollagen and
inhibits their spontaneous apoptosis (Scaffidi et al., 2002). In
addition, OSM was demonstrated to be a potent mediator of
lung inflammation and ECM accumulation. Furthermore, the
upregulation of OSM was observed in the bronchoalveolar
lavage fluid of patients with pulmonary fibrosis (Mozaffarian
et al., 2008). Lim et al. (2009) reported OSM to be upregulated
in keloid fibroblast–keratinocyte coculture while being absent
in NF–keratinocyte coculture. This phenomenon can be
perfectly explained contemplating our own data: normal
keratinocytes only secrete OSM when stimulated with
increased amounts of KGF as found in keloid and sclero-
derma. Our data demonstrate that keratinocytes release OSM
in a KGF-dependent manner, which in turn induces fibroblast
activation. Treating keratinocytes with siRNA against KGFR,
we could suppress the elevated OSM expression upon KGF
treatment. This finding suggests that KGFR inhibitors, such as
SU5402 (Li et al., 2009), could be valuable drugs in the
treatment of cutaneous fibrosis.
Although OSM is most likely not the only cytokine released
by keratinocytes exerting profibrotic effects on fibroblasts, it
surely is an important factor. First, it was the only cytokine
found to be upregulated in KCM as a function of KGF
stimulation and, second, OSM is sufficient and necessary for
the mediation of STAT3 phosphorylation.
In keloid scar tissue, STAT3 expression and phosphorylation
are well known to be enhanced (Lim et al., 2006). In keloid
fibroblast–keratinocytes cocultures, where OSM expression is
increased, STAT3 phosphorylation was also shown to be
highest (Lim et al., 2009). As we could suppress fibroblast
activation by inhibition of STAT3 signaling, it could be
demonstrated that the pathological features of keloids could
be prevented using a green tea polyphenol to inhibit STAT3
phosphorylation (Park et al., 2008). In addition, STAT3
activation was demonstrated to increase the expression of
numerous profibrotic genes in a variety of tissues. For
instance, it is known to have a role in regulating fibroblast
function in fibrotic lung diseases (Pechkovsky et al., 2012).
Furthermore, the application of STAT3 inhibitors resulted in a
significant decrease in cardiac fibroblast collagen synthesis in
an in vivo cardiac hypertrophy rat model (Mir et al., 2012). In
addition, the administration of the STAT3 inhibitor S3I-201
attenuated ECM deposition, following injury in a mouse
model of renal interstitial fibrosis (Pang et al., 2010).
Moreover, we were able to show that the increased
fibroblast migration induced by the cytokine interplay of
KGF and OSM depends on the STAT3-targeted urokinase-
mediated plasminogen activation (uPA) system. This system
has a central role in a number of cellular processes, including
tissue remodeling, cell migration, and angiogenesis. Elevated
uPA activity has also been correlated with tumor invasion and
metastasis in a variety of malignancies. The uPA system is
involved in the expansion of keloids beyond the wound
margins in part through the degradation of the ECM, a finding
that is supported by the strong expression of uPAR in the ECM
and collagenous cords in most keloids studied (Leake et al.,
2003). Furthermore, recent findings also suggest that uPA has
a role in the limited form of systemic sclerosis, likely related
to the activation of latent forms of cytokines and to the
accumulation of ECM components (Postiglione et al., 2010).
Cancer cells of epithelial origin, which express both KGF and
KGFR, were shown to induce cell migration via uPA in an
autocrine NF-kB-dependent manner (Niu et al., 2007). In
addition, endothelial cell migration can also be triggered by
OSM-induced uPA expression (Strand et al., 2000). Most stri-
kingly, our discovery of uPA inducing collagen synthesis was
confirmed for pleural mesothelial cells (Tucker et al., 2012).
Being able to actually induce the KGF effects initially
observed in vitro in real human skin substantiates the
importance and relevance of our results. Many seemingly
unrelated pieces of the highly complex puzzle of epithelial–
mesenchymal cross talk in cutaneous fibrosis have already
been discovered and our work puts many of them together
while adding further important information and providing an
idea of the pathogenesis of cutaneous fibrosis previously
unreported to our knowledge. Fibroblast–keratinocyte interac-
tions were known to be crucial in tissue homeostasis for more
than three decades (Maas-Szabowski et al., 1999), but to our
knowledge the overexpression of KGF in the mesenchymal
cells of individuals suffering from cutaneous fibrosis and its
consequences has not been described before. With our study
we add to the understanding of dermal fibrogenesis by
proposing a double paracrine mode of fibroblast activation
causative for fibrosing disorders of the skin induced by the
persistent upregulation of KGF, and thereby offering a variety
of targets for therapeutical approaches.
MATERIALS AND METHODS
Cell isolation and cell culture conditions
Normal human fibroblasts (n¼ 8) were partially purchased from
Cambrex (Charles City, Charles City, IA) and isolated from adult
tissue kindly provided by the Department of Dermatology of the
University hospital of Regensburg, Germany.
Handling and sampling of human tissue material and sera, as well
as fibroblast isolation from keloid (n¼ 4) and localized scleroderma
(n¼ 5) patients was approved by the ethical committee of the
University of Regensburg (application number 09/11 and 03/151).
All fibroblasts were maintained in DMEM supplemented with
penicillin (400 U ml 1), streptomycine (50 mg ml 1), L-glutamine
(300 mg ml 1), and 10% fetal calf serum (Sigma Aldrich, Deisenhofen,
Germany) and split 1:3 every 5 days.
Culture of human skin samples
Human skin pieces were cut in 1-cm2 squares and embedded in 2 ml
HEPES agar with 1 ml DMEM with 10% FCS per well in six-well
plates. After 24 and 48 hours, respectively, the skin pieces were
grinded up in a mortar with 10 ml liquid nitrogen each. The
powdered skin samples were dissolved in and homogenized using
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E.Z.N.A. Homogenizer Spin Columns (Omega Bio-Tek, Norcross,
GA). Subsequently, RNA was isolated using the E.Z.N.A. Total RNA
Kit I (Omega Bio-Tek). The study is conducted in accordance with the
Declaration of Helsinki Principles. Handling of human skin was
approved by the ethical committee of the University of Regensburg
(application number 09/11 and 03/151). As no patient-specific data
were used in the study, and tissue left after surgery and the final
diagnosis are considered as discarded materials under German law,
written informed patient consent is not required.
Treatment with recombinant proteins and inhibitors
Xeno-free recombinant human KGF was obtained from Humanzyme
(Chicago, IL; HZ 1095) and recombinant human OSM from Abnova
(Taipei City, Taiwan; H00005008-P01). The small molecule Calbio-
chem STAT3-inhibitor S3I-201 was purchased from Merck Millipore
(Darmstadt, Germany). The treatment conditions are listed in
Supplementary Table S2 online.
RNA isolation and reverse transcription
Total cellular RNA was isolated from the respective cells using the
E.Z.N.A. Total RNA Kit I (Omega Bio-Tek) and complementary DNAs
were generated as described elsewhere (Braig et al., 2011).
RNA extraction from FFPE (formalin-fixed paraffin-embedded)
tissue
For preparation of RNA from FFPE samples, the RNeasy FFPE kit
(QIAGEN, Hilden, Germany) was used according to the manufac-
turer’s recommendations.
Analysis of expression by quantitative RT-PCR
Quantitative real time-PCR for KGF, ColIa1, FAP, OSM, uPA, and b-actin
were performed by means of LightCycler480 II technology (Roche,
Penzberg, Germany). One microliter of complementary DNA template,
0.5ml (20mM) of primers (Supplementary Table S3 online), 8ml H2O, and
10ml LightCycler480 SYBR Green I Master were combined to a total
volume of 20ml. The PCR program was composed of the following steps:
initial denaturation at 95 1C for 10minutes, followed by 45 cycles of am-
plification with 10 seconds at 95 1C, 10seconds at 60 1C, and 20seconds
at 72 1C. PCR reactions were evaluated by melting curve analysis.
ELISA
Supernatants and patient sera were analyzed using human KGF ELISA
(R&D, Wiesbaden-Nordenstadt, Germany) or human OSM ELISA
(RayBioTech, Norcross, GA) according to the manufacturer’s guidelines.
Immunohistochemistry
Paraffin-embedded preparations of normal skin, keloid, and scler-
oderma tissue were screened for KGF protein expression as described
elsewhere (Braig et al., 2011) using a rabbit anti-FGF7 (H73; sc-7882)
antibody (1:100, Santa Cruz Biotechnology, Santa Cruz, CA).
Scratch assay (wound healing assay)
Cells were seeded in high density into six-well plates (200 000 cells
per well) and scratched with a pipette tip in a definite array. Migration
into this array was documented and measured after 12 and 24 hours
using a Carl Zeiss microscope (Carl Zeiss Vision, Oberkochen,
Germany). Absolute migration was displayed in micrometer. Each
analysis was performed in duplicates and was repeated three times.
Transfection
siRNAs against KGF, uPA, and KGFR were obtained from Qiagen
(Hilden, Germany), as well as a suitable control siRNA. siRNAs were
transfected into the respective cells using Lipofectamin2000 reagent
(Life Technologies, Darmstadt, Germany). Knockdown efficiency was
controlled using RT-PCR and was within the bounds of 70–90%.
Plasmid transfection was carried out by means of LipofectaminLTX
(Life Technologies). All transfection procedures were carried out
according to the manufacturer’s instructions.
Human cytokine antibody array
RayBio Cytokine Array V (RayBiotech, Norcross, GA) was performed
according to the manufacturer’s instructions to detect the cytokine
expression in the supernatants of normal human epidermal keratino-
cytes after 24 hours incubation with 25 ng recombinant human KGF
per microliter compared with the untreated control. Photoshop
(Adobe, San Jose, CA) was used to determine spot density.
Western blotting
In vitro protein analysis was performed as described elsewhere (Braig
et al., 2011). Primary antibodies used are: anti-STAT3 (Cell Signaling,
Danvers, MA; 124H6, mouse, 1:1,000), anti-P(Y705)-STAT (Cell
Signaling; D3A7, rabbit, 1:1,000), and b-actin (Sigma Aldrich,
Hamburg, Germany, 1:2,500).
Statistical analysis
Results are expressed as mean±SD (range) or percent. Comparisons
between two groups were made using the Mann–Whitney test as
no5 in these experiments. Analysis of variance (ANOVA) with
Tukey post hoc analysis (n45) or Kruskal–Wallis test (no5) were
used for comparisons of more than two groups. A P-value o0.05
was considered statistically significant (*Po0.05; **Po0.01;
***Po0.001). All calculations were performed using the GraphPad
Prism software (San Diego, CA).
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